[ad_1] Recently co-authored with Enoch Kassa, Rehan Hussain, and Pravin U Dugel MD : https://www.tandfonline.com/eprint/Eh34pFrtUA4ZVmjw3INp/full?target=10.1080/14712598.2019.1575358 Complement inhibition as a therapeutic strategy in retinal disorders (2019). Complement inhibition as a therapeutic strategy in retinal disorders. Expert Opinion on Biological Therapy. Ahead of Print. [ad_2] Return to …
[ad_1] Recently co-authored with Drs. Peter Bracha and Caroline Baumal: https://www.healio.com/ophthalmology/journals/osli/2018-10-49-10/%7Bc1b5894d-ccc7-46f1-8218-5066fc7cc7aa%7D/vital-dyes-in-vitreomacular-surgery Vital Dyes in Vitreomacular Surgery Ophthalmic Surgery, Lasers and Imaging Retina | Vital dyes contain complex molecules with chromophores that stain living tissues and have greatly enhanced identification and removal of transparent vitreoretinal tissues …
[ad_1]
Recently co-authored a retrospective study of nearly 16,000 patients with diabetic macular edema (DME), a common cause of visual impairment:
At 1 year, despite treatment, real-world DME patients have meaningfully worse visual outcomes compared to patients in randomized controlled trials, and those with well-preserved baseline vision are particularly prone to vision loss.
https://www.sciencedirect.com/science/article/abs/pii/S2468653018302653
This study assessed real-world visual acuity (VA) outcomes of anti–vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (…
[ad_2]
Return to main website.
[ad_1] Just published this review on Stargardt Macular Dystrophy with colleagues from Bascom Palmer… Stargardt macular dystrophy and evolving therapies (2018). Stargardt macular dystrophy and evolving therapies. Expert Opinion on Biological Therapy: Vol. 18, No. 10, pp. 1049-1059. [ad_2] Return to main website.
[ad_1] Honored to have been interviewed on retinal innovation and the role of academia, clinical practice and industry… https://lnkd.in/erS9_pq Retinal Physician – RETINA CONVERSATIONS: A Conversation With Thomas A. Ciulla, MD, MBA Retinal Physician interviews a retina specialist whose career has gone from clinical to …
[ad_1]
Thomas A. Ciulla, M.D. added 2 new photos.
[ad_2]
Return to main website.
[ad_1] Just published in Retina Today on development of retinal orphan and gene therapies…. Retina Today – New Directions on the Drug Development Pathway The development of therapies for orphan retinal diseases and genetic disorders differs from that of traditional treatments. [ad_2] Return to main …
Video-interviewed on a clinical study of nearly 50,000 AMD patients…
Real-World Outcomes of nAMD Treated With Anti-VEGF Therapy
Thomas A. Ciulla, MD, details a study that examined change of visual acuity versus frequency of anti-VEGF injections over 1 year in patients with neovascular age-related macular degeneration (nAMD). Dr. Ciulla points out key lessons that this study d…
[ad_2]
Return to main website.
[ad_1] Drs Rehan Hussain and Ciulla just published in Retina Insider on long-acting and sustained released anti-VEGF therapies… http://www.reviewofophthalmology.com/article/addressing-the-antivegf-treatment-burden Addressing the Anti-VEGF Treatment Burden Rehan M. Hussain, MD, Miami, and Thomas A. Ciulla, MD, MBA, Indianapolis Published 12 March 2018 Addressing the Anti-VEGF Treatment Burden …